Your session is about to expire
What is Uptravi
Approved as Treatment by the FDA
Selexipag, otherwise known as Uptravi, is approved by the FDA for 1 uses such as Pulmonary Arterial Hypertension .Effectiveness
When to interrupt dosage
The proposed dosage of Uptravi is contingent upon the diagnosed condition. The measure additionally fluctuates as per the technique of conveyance (e.g. Tablet, coated - Oral or Tablet, film coated) featured in the accompanying table.Warnings
Uptravi has two contraindications, so it should not be employed while suffering from the conditions in the following table.Uptravi ContraindicationsUptravi Novel Uses: Which Conditions Have a Clinical Trial Featuring Uptravi?
53 ongoing trials are studying the utility of Uptravi in providing therapeutic benefit for Pulmonary Arterial Hypertension.Uptravi Reviews: What are patients saying about Uptravi?
Patient Q&A Section about uptravi
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What class of drug is UPTRAVI?
"Uptravi is a medication used to treat Pulmonary Arterial Hypertension. Uptravi works by relaxing the blood vessels in your lungs which lowers your blood pressure. Uptravi may be used alone or in combination with other medications."
What is UPTRAVI used for?
"UPTRAVI® is a prescription medication used to treat pulmonary arterial hypertension (a condition characterized by high blood pressure in the arteries of the lungs). UPTRAVI® can help to slow the progression of the disease and reduce the risk of hospitalization for PAH."
Does UPTRAVI lower blood pressure?
"This medication lowers blood pressure by widening blood vessels in your lungs. It is used to treat pulmonary arterial hypertension and can help prevent your condition from worsening or reduce your risk of needing to be hospitalized."
Is UPTRAVI FDA approved?
"- Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients."